LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Harvard Bioscience Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

0.73 -3.95

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

0.72

Max

0.76

Pagrindiniai rodikliai

By Trading Economics

Pajamos

1.1M

-1.2M

Pardavimai

141K

21M

Pelno marža

-5.978

Darbuotojai

330

EBITDA

1M

1.2M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+163.16% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

8.2M

34M

Ankstesnė atidarymo kaina

4.68

Ankstesnė uždarymo kaina

0.73

Naujienos nuotaikos

By Acuity

26%

74%

84 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Harvard Bioscience Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-10 22:02; UTC

Uždarbis

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

2025-12-10 21:46; UTC

Uždarbis

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

2025-12-10 23:52; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

2025-12-10 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise After Fed Rate Cut -- Market Talk

2025-12-10 23:36; UTC

Rinkos pokalbiai

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

2025-12-10 23:20; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

2025-12-10 23:15; UTC

Uždarbis

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

2025-12-10 22:59; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

2025-12-10 22:45; UTC

Rinkos pokalbiai

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

2025-12-10 22:40; UTC

Uždarbis

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025-12-10 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025-12-10 22:06; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025-12-10 22:02; UTC

Uždarbis

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

2025-12-10 22:00; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

2025-12-10 21:53; UTC

Uždarbis

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025-12-10 21:50; UTC

Įsigijimai, susijungimai, perėmimai

Investors Bet That a Higher Bid for Warner Is Coming -- Update

2025-12-10 21:50; UTC

Rinkos pokalbiai
Uždarbis
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-12-10 21:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-12-10 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-10 21:45; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

2025-12-10 21:33; UTC

Uždarbis

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

2025-12-10 21:32; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

2025-12-10 21:28; UTC

Įsigijimai, susijungimai, perėmimai

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

2025-12-10 21:25; UTC

Uždarbis

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

2025-12-10 21:18; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

2025-12-10 21:16; UTC

Uždarbis

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

2025-12-10 21:15; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

2025-12-10 21:15; UTC

Uždarbis

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

2025-12-10 21:14; UTC

Uždarbis

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

2025-12-10 21:14; UTC

Uždarbis

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Akcijų palyginimas

Kainos pokytis

Harvard Bioscience Inc Prognozė

Kainos tikslas

By TipRanks

163.16% į viršų

12 mėnesių prognozė

Vidutinis 2 USD  163.16%

Aukščiausias 2 USD

Žemiausias 2 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harvard Bioscience Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

0.3 / 0.3401Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

No Evidence

Ilgalaikis periodas

No Evidence

Rinkos nuotaikos

By Acuity

84 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat